Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 2/20 | 0.35 |
| ▸ | CES1 | P23141 | 2/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6744464 | 0.77 | ERN1 (0.57) | ERN1CES2CES1ESR1ESR2 | |
| SCHEMBL29629103 | 0.77 | ERN1 (0.57) | ERN1CES2CES1ESR1ESR2 | |
| SCHEMBL16958836 | 0.76 | CES2 (0.43) | ERN1CES2CES1 | |
| SCHEMBL3986050 | 0.74 | ESR1 (0.31) | ESR1ESR2 | |
| SCHEMBL919665 | 0.74 | KDM1A (0.42) | ERN1CES2CES1 | |
| SCHEMBL31249671 | 0.73 | ERN1 (0.38) | ERN1CES2CES1 | |
| SCHEMBL19224593 | 0.73 | ERN1 (0.38) | ERN1CES2CES1 | |
| SCHEMBL29583421 | 0.72 | ERN1 (0.38) | ERN1CES2CES1 | |
| SCHEMBL6553272 | 0.72 | KDM1A (0.41) | ERN1CES2CES1 | |
| SCHEMBL30864257 | 0.71 | KDM1A (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260091048-A1 | GIP RECEPTOR AGONIST COMPOUNDS | LILLY CO ELI (US) | 2026-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091048-A1 | GIP RECEPTOR AGONIST COMPOUNDS | GIPR, GLP1R, GPR119 | ERN1 3871/4885CES2 1537/4885CES1 960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.